Drugs / 18F-Alfatide
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06416852 | Aug 2024 → Aug 2026 overdue | non-small cell lung carcinoma | Yantai LNC Biotechnology Singapore PTE. LTD. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 18F-Alfatide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06416852 ↗ |
| Modality | Diagnostic / imaging agent | “18F-Alfatide Injection PET/CT” NCT06416852 ↗ |
| Route | Intravenous | “IV injection of 18F-Alfatide” NCT06416852 ↗ |